Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 June 2025 | Story Tshepo Tsotetsi | Photo Supplied
Dr Herkulaas Combrink
Dr Herkulaas Combrink is representing UFS in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Herkulaas Combrink, a senior lecturer in the Faculty of Economic and Management Sciences (EMS) at the University of the Free State (UFS), is representing the university in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Combrink, who is also a co-director of the Interdisciplinary Centre for Digital Futures (ICDF), has been selected as one of the principal investigators in a newly funded project supported by the UK’s International Science Partnerships Fund under the Evidence-Informed Policymaking Programme. Running from April 2025 to March 2026, the project – titled Integrating Evidence for Contextualised Public Health Policy: Lessons from South Africa – explores how different types of evidence can be used more effectively in shaping public health policy. The international collaboration includes researchers from the Centre for Philosophy of Epidemiology, Medicine and Public Health, which is a collaboration between Durham University and the University of Johannesburg; as well as Durham’s Centre for Humanities Engaging Science and Society.

 

From the Free State to global impact

For Dr Combrink, being part of this collaboration highlights the important work being done in the faculty and ICDF that is reaching beyond borders. 

“It’s important to showcase the impact we are making from the Free State that leads to global outcomes,” he said.

The project aims to evaluate an evidence mapping framework to determine how model-based projections and social listening reports can be more effectively integrated and contextualised for policymaking.

“These are two very different data types,” he explained. “The value lies in demonstrating how to apply the framework to different contexts for evidence-based mapping.”

Dr Combrink brings extensive expertise to the team, having worked on both disease modelling and risk communication during South Africa’s COVID-19 response. He was involved in national and provincial social listening initiatives, and used high-frequency social media data to track the spread of misinformation, often referred to as the ‘infodemic.’ 

“We’ve built up enough data within ICDF and EMS to support this study,” he noted.

The goal is not just theoretical. A key outcome of the project is engaging directly with policymakers to refine modelling and risk communication strategies for future pandemics. 

“This will help us to engage with the various departments of health to assist with improving modelling and risk communication work for better social behavioural change,” he explained.

According to Prof Brownhilder Neneh, Vice-Dean for Research and Internationalisation in the EMS faculty, the project reflects the faculty’s growing global presence. 

“Dr Combrink’s participation is a testament to the calibre of scholarship within the faculty,” she said. “It positions EMS as a key contributor to shaping policy and practice with societal impact.”

She added that the collaboration aligns well with the faculty’s vision for global partnerships that are rooted in local relevance.

“By focusing on contextualised evidence for policymaking, this project reflects our commitment to relevance, engagement and global partnership,” she said.

 

What comes next

Over the project’s 12-month timeline, the team will deliver:

• a case study analysis of modelling and social listening during South Africa’s COVID-19 response;
• an extended evidence mapping framework tailored to diverse evidence types;
• policy briefs and practical tools for public health practitioners; and
• a hybrid international workshop in late 2025 bringing together researchers, policymakers and health professionals to test and refine these outputs.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept